Stock INBX INHIBRX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Inhibrx, Inc.

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 10:28:44 2024-06-04 am EDT 		5-day change 1st Jan Change
18.14 USD +0.67% Intraday chart for Inhibrx, Inc. -46.81% -51.92%
May. 31 Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index CI
May. 31 Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,243 1,657 1,073 1,797 1,787 - -
Enterprise Value (EV) 1 1,144 1,597 1,001 1,797 1,787 1,787 1,787
P/E ratio -11 x -20.3 x -6.81 x -7.42 x -5.82 x -6.9 x -6.77 x
Yield - - - - - - -
Capitalization / Revenue 96.5 x 229 x 490 x 998 x - 896 x 14.7 x
EV / Revenue 96.5 x 229 x 490 x 998 x - 896 x 14.7 x
EV / EBITDA -18,718,797 x -21,991,725 x -8,390,728 x - - - -
EV / FCF -25,204,277 x -20,415,760 x -9,251,959 x - - - -
FCF Yield -0% -0% -0% - - - -
Price to Book 11 x 32.5 x 18.5 x - - - -
Nbr of stocks (in thousands) 37,712 37,955 43,551 47,291 52,402 - -
Reference price 2 32.97 43.67 24.64 38.00 34.11 34.11 34.11
Announcement Date 3/12/21 2/28/22 3/6/23 2/28/24 - - -
1USD in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12.89 7.231 2.192 1.8 - 1.995 122
EBITDA -66.42 -75.37 -127.9 - - - -
EBIT 1 -67.44 -76.56 -129.1 -219.2 -303.9 -360.6 -296.4
Operating Margin -523.3% -1,058.83% -5,890.37% -12,178.94% - -18,074.19% -243.07%
Earnings before Tax (EBT) 1 -75.63 -81.77 -145.2 -239.7 -313.6 -360.6 -296.4
Net income 1 -76.12 -81.77 -145.2 -241.4 -316 -360.6 -296.4
Net margin -590.66% -1,130.8% -6,625.27% -13,408.94% - -18,074.19% -243.07%
EPS 2 -3.010 -2.150 -3.620 -5.120 -5.865 -4.940 -5.040
Free Cash Flow -49.33 -81.19 -116 - - - -
FCF margin -382.77% -1,122.76% -5,291.38% - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/12/21 2/28/22 3/6/23 2/28/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position 99.4 60.8 71.8 - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -49.3 -81.2 -116 - - - -
ROE (net income / shareholders' equity) - -128% -263% - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2.990 1.340 1.330 - - - -
Cash Flow per Share -1.900 -2.110 -2.870 - - - -
Capex 1.36 0.86 0.69 - - - -
Capex / Sales 10.58% 11.95% 31.3% - - - -
Announcement Date 3/12/21 2/28/22 3/6/23 2/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INHIBRX, INC. Stock Inhibrx, Inc.
-51.92% 1.79B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.46% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.56% 107B
BIONTECH SE Stock BioNTech SE
-4.67% 24.82B
ARGENX SE Stock argenx SE
+1.51% 22.48B
GENMAB A/S Stock Genmab A/S
-9.86% 18.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.28% 16.33B
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.08% 15.31B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.08% 14.08B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+26.22% 11.74B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. INBX Stock
  4. Financials Inhibrx, Inc.